The incidence of symptomatic osteonecrosis is similar between Japanese children and children in Western countries with acute lymphoblastic leukaemia treated with a Berlin‐Frankfurt‐Münster (BFM)95‐based protocol. (8th December 2021)

• Record Type: Journal Article
• Authors: Moriya, Kunihiko; Imamura, Toshihiko; Katayama, Saori; Kaino, Akira; Okamoto, Kenji; Yokoyama, Norihumi; Uemura, Suguru; Kitazawa, Hironobu; Sekimizu, Masahiro; Hiramatsu, Hidefumi; Usami, Ikuya; Ishida, Hisashi; Hasegawa, Daiichiro; Hama, Asahito; Moriya‐Saito, Akiko; Sato, Atsushi; Sasahara, Yoji; Suenobu, Souichi; Horibe, Keizo; Hara, Junichi
• Is Part Of: British journal of haematology. Volume 196:Number 5(2022)
• Page Start: 1257
• Page End: 1261
• Publication Date: 2021-12-08
• Subjects: osteonecrosis -- acute lymphoblastic leukaemia -- Berlin‐Frankfurt‐Münster (BFM)95‐based protocol -- Japanese children; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15
• DOI: 10.1111/bjh.17988
• Languages: English
• ISSNs: 0007-1048

Abstract

Summary: In this study, we performed a retrospective analysis of a cohort of Japanese paediatric patients with B‐cell precursor (BCP)‐acute lymphoblastic leukaemia (ALL) treated with a Berlin‐Frankfurt‐Münster (BFM)95‐based protocol, to clarify the incidence, clinical characteristics, and risk factors of osteonecrosis (ON) in comparison to the ALL‐02 protocol. We identified a high frequency of ON with the BFM95‐based protocol compared to the ALL‐02 protocol. The incidence of symptomatic ON with the BFM95‐based protocol is comparable to previous studies in Western countries. We believe that the type of treatment regimen has more impact on the incidence of symptomatic ON in paediatric ALL than ethnicity.